Grayson M L, Grabsch E A, Johnson P D, Olden D, Aberline M, Li H Y, Hogg G, Abbott M, Kerr P G
Infectious Disease and Clinical Epidemiology Department, Monash Medical Center, Melbourne, VIC.
Med J Aust. 1999 Aug 2;171(3):133-6. doi: 10.5694/j.1326-5377.1999.tb123564.x.
To screen for faecal colonisation with vancomycin-resistant enterococci (VRE) among potentially at-risk patients.
Infection control screening program.
Monash Medical Centre (a tertiary care hospital), Melbourne, Victoria, in the seven months from June 1997.
Patients in the Renal, Oncology and Intensive Care (ICU) Units.
Presence of VRE in a rectal swab or faecal specimen taken at admission and at regular intervals during inpatient stay; presence of vancomycin-resistance genes (vanA, vanB and vanC) assessed by polymerase chain reaction (PCR); genetic clonality of isolates assessed by pulsed-field gel electrophoresis (PFGE).
574 patients (356 renal, 134 ICU and 84 oncology) were screened; 12 were colonised with VRE--nine renal inpatients, two having peritoneal dialysis or incentre haemodialysis, and one ICU patient. Nine isolates were Enterococcus faecalis (seven positive for vanB and two negative for all three resistance genes) and three were Enterococcus faecium (all positive for vanB). Eight were high-level gentamicin resistant. PFGE suggested genetic clonality between the index isolate and five other isolates from renal patients. No specific clinical practice was associated with VRE colonisation. Attempts to clear rectal carriage with oral ampicillin/amoxycillin or bacitracin were of limited success. Although antibiotic prescribing in the Renal Unit was generally consistent with defined protocols, use of vancomycin and third-generation cephalosporins has been further restricted.
Renal inpatients in our institution appear most at risk of VRE colonisation (4.6% overall) and therefore of VRE infection. Routine screening, especially of potentially high-risk patients, should be considered in major Australian hospitals.
在潜在高危患者中筛查耐万古霉素肠球菌(VRE)的粪便定植情况。
感染控制筛查项目。
1997年6月起的7个月内,位于维多利亚州墨尔本的莫纳什医疗中心(一家三级护理医院)。
肾脏科、肿瘤科和重症监护病房(ICU)的患者。
入院时及住院期间定期采集的直肠拭子或粪便标本中VRE的存在情况;通过聚合酶链反应(PCR)评估万古霉素耐药基因(vanA、vanB和vanC)的存在情况;通过脉冲场凝胶电泳(PFGE)评估分离株的基因克隆性。
共筛查了574例患者(356例肾脏科患者、134例ICU患者和84例肿瘤科患者);12例患者被VRE定植,其中9例为肾脏科住院患者,2例进行腹膜透析或中心血液透析,1例为ICU患者。9株分离株为粪肠球菌(7株vanB阳性,2株所有三种耐药基因均为阴性),3株为屎肠球菌(均为vanB阳性)。8株对高水平庆大霉素耐药。PFGE显示首例分离株与来自肾脏科患者的其他5株分离株之间存在基因克隆性。VRE定植与任何特定临床实践均无关联。口服氨苄西林/阿莫西林或杆菌肽清除直肠定植的尝试效果有限。尽管肾脏科的抗生素处方总体上符合既定方案,但万古霉素和第三代头孢菌素的使用已进一步受限。
我们机构中的肾脏科住院患者似乎最易发生VRE定植(总体发生率为4.6%),因此也最易发生VRE感染。澳大利亚的大型医院应考虑进行常规筛查,尤其是对潜在高危患者。